HRES 1265
Expressing support for the designation of the week of May 3, 2026, through May 9, 2026, as "Tardive Dyskinesia Awareness Week".
Take action
Record your position on this measure.
Sign in to record your position, submit testimony, or contact your legislator.
Sign in to take action- Introduced
- Passed House
- Passed Senate
- To President
- Became Law
Bill overview
This resolution urges support for designating the week of May 3-9, 2026, as ‘Tardive Dyskinesia Awareness Week’. It highlights the serious neurological movement disorder, tardive dyskinesia (TD), which can be a side effect of medications used to treat mental and gastrointestinal illnesses. The resolution aims to raise public and medical community awareness about TD, its prevalence, and the importance of early detection and treatment.
Key provisions
- Designates the week of May 3-9, 2026, as Tardive Dyskinesia Awareness Week.
- Encourages public awareness of tardive dyskinesia.
- Recognizes that TD can be a side effect of antipsychotics and antiemetics.
- Acknowledges the significant number of undiagnosed cases of TD.
- Recommends monitoring for TD by healthcare providers.
- Highlights the importance of screening for TD.
- References the American Psychiatric Association's recommendations for screening.
- Notes the FDA approval of treatments for TD.
Who is affected
- People with mental illnesses (bipolar disorder, depression, schizophrenia, schizoaffective disorder)
- People with gastrointestinal disorders (gastroparesis, nausea, vomiting)
- Healthcare providers
- The general public
- Individuals at risk of developing tardive dyskinesia
Notable changes
- The resolution focuses on raising awareness of a specific, often undiagnosed, side effect of medication.
Sponsors
Official sponsors from legislative records.
Primary sponsor
Cosponsors
Arguments in favor
Reasons to support this legislation.
No arguments in favor have been submitted.
Submit yoursArguments opposed
Reasons to oppose this legislation.
No arguments opposed have been submitted.
Submit yoursRead the latest version inline or switch to a previous version.
119th CONGRESS — 2d Session
H. RES. 1265
IN THE HOUSE OF REPRESENTATIVES
RESOLUTION
Expressing support for the designation of the week of May 3, 2026, through May 9, 2026, as Tardive Dyskinesia Awareness Week
.
Whereas many people living with serious mental illnesses (for example, bipolar disorder, major depressive disorder, schizophrenia, and schizoaffective disorder) or gastrointestinal disorders (for example, gastroparesis, upset stomach, nausea, and vomiting) may be treated with medications that work as dopamine receptor blocking agents, including antipsychotics and antiemetics;
Whereas, while ongoing treatment with these medications can be necessary, prolonged use may be associated with tardive dyskinesia (TD), an involuntary movement disorder that is characterized by uncontrollable, abnormal, and repetitive movements of the face, torso, limbs, and fingers or toes;
Whereas even mild symptoms of TD can impact people physically, socially, and emotionally;
Whereas it is estimated that TD affects approximately 600,000 people in the United States, and approximately 60 percent of people with TD have not been diagnosed, making it important to raise awareness about the symptoms;
Whereas it is important that people taking these medications be monitored for TD by a health care provider, and regular screening for TD is recommended by the American Psychiatric Association;
Whereas clinical research has led to approval of treatments for adults with TD by the Food and Drug Administration, and recognition and treatment of TD can make a positive impact in the lives of many people experiencing psychotic and mood disorders; and
Whereas the House of Representatives can raise awareness of TD among the public and medical community: Now, therefore, be it
That the House of Representatives—
expresses support for the designation of Tardive Dyskinesia Awareness Week
; and